GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » Price-to-Owner-Earnings

Coherus BioSciences (Coherus BioSciences) Price-to-Owner-Earnings : (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Price-to-Owner-Earnings?

As of today (2024-04-29), Coherus BioSciences's share price is $2.07. Coherus BioSciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Coherus BioSciences's Price-to-Owner-Earnings or its related term are showing as below:

During the past 12 years, the highest Price-to-Owner-Earnings of Coherus BioSciences was 31.11. The lowest was 13.21. And the median was 19.92.


CHRS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.12
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-29), Coherus BioSciences's share price is $2.07. Coherus BioSciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.60. Therefore, Coherus BioSciences's PE Ratio for today is At Loss.

As of today (2024-04-29), Coherus BioSciences's share price is $2.07. Coherus BioSciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.60. Therefore, Coherus BioSciences's PE Ratio without NRI for today is At Loss.

During the past 12 years, Coherus BioSciences's highest PE Ratio without NRI was 18.93. The lowest was 0.00. And the median was 8.84.


Coherus BioSciences Price-to-Owner-Earnings Historical Data

The historical data trend for Coherus BioSciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Price-to-Owner-Earnings Chart

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 15.80 - - -

Coherus BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Coherus BioSciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Coherus BioSciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Price-to-Owner-Earnings falls into.



Coherus BioSciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Coherus BioSciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.07/-2.45
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coherus BioSciences  (NAS:CHRS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Coherus BioSciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences (Coherus BioSciences) Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Executives
Dennis M Lanfear director, officer: President and CEO C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell officer: Chief Financial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael officer: See Remarks C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider officer: Chief Commercial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton director 46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler officer: Chief Scientific Officer 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti officer: Chief, Quality & Compliance COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper director 150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson director ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas director 1170 FAIRFAX STREET, BIRMINGHAM MI 48009